2-benzyl-6,7-dimethoxy-3H-quinazolin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-benzyl-6,7-dimethoxy-3H-quinazolin-4-one
• 英文别名: 2-Benzyl-6,7-dimethoxy-3H-chinazolin-4-on；2-benzyl-6,7-dimethoxy-4(3H)-quinazolinone；2-benzyl-6,7-dimethoxy-3H-quinazolin-4-one
• 化学式: C₁₇H₁₆N₂O₃
• 分子量: 296.326
• InChiKey: LRKOOFPVPJYOBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  59.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-氨基-4,5-二甲氧基苯甲酸甲酯 、 苯乙腈 生成 2-benzyl-6,7-dimethoxy-3H-quinazolin-4-one
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• [EN] SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1<br/>[FR] AGONISTES À PETITES MOLÉCULES DE RÉCEPTEUR DE NEUROTENSINE 1
  申请人：SANFORD BURNHAM MED RES INST

  公开号：WO2014100501A1

  公开（公告）日：2014-06-26

  Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

  提供的是小分子神经降压素受体激动剂，包含这些化合物的组合物，以及使用这些化合物和包含这些化合物的组合物的方法。
• Tautomeric equilibria of 2- and 4-thiouracil in gas phase and in solvent: A density functional study
  作者：T. Marino、N. Russo、E. Sicilia、M. Toscano

  DOI：10.1002/1097-461x(2001)82:1<44::aid-qua1020>3.0.co;2-6

  日期：——

  self-consistent reaction field approach by the polarizable continuum model. All calculations indicate that the most stable tautomer for both species, in the gas phase as well as in solution, has the oxo-thione form, in full agreement with the previous ab initio and experimental studies. The tautomeric stability orders obtained in the aqueous solution are sensibly different from that in the gas phase. At B3LYP/6-311++G(d

  气相和水溶液中 2- 和 4-硫尿嘧啶的五种有利互变异构体的相对稳定性通过密度泛函理论采用 Becke、Lee、Yang 和 Parr (B3LYP) 交换相关势和三个 6- 31G(d,p)、6-311++G(d,p) 和三 zeta 价 (TZVP) 基组。还计算了零点振动校正。通过可极化连续介质模型在自洽反应场方法的框架内研究了本体溶剂效应。所有计算表明，两种物质在气相和溶液中最稳定的互变异构体都具有氧代硫酮形式，这与之前的从头计算和实验研究完全一致。在水溶液中获得的互变异构稳定性顺序明显不同于在气相中的互变异构稳定性顺序。在 B3LYP/6-311++G(d, p) 在气相中，2-和 4-硫尿嘧啶互变异构体的稳定性顺序分别为：S2U1>S2U2>S2U4>S2U5>S2U3 和 S4U1>S4U2>S4U3>S4U4>S4U5。水相中相应的趋势是S2U1>S2U3>S2U2>S2U
• Microwave-assisted annulation for the construction of pyrido-fused heterocycles and their application as photoluminescent chemosensors
  作者：Ei Seul Yun、Muhammad Saeed Akhtar、Sonaimuthu Mohandoss、Yong Rok Lee

  DOI：10.1039/d2ob00257d

  日期：——

  3-formylchromones to yield functionalized 11H-pyrido[2,1-b]quinazolin-11-one and pyrido[1,2-a] benzimidazole derivatives. This approach is successfully extended to the construction of various pyrazolo[4,3-d]pyrido[1,2-a]pyrimidin-10(1H)-ones. The present approach is complementary to the existing synthetic methodologies and offers a rapid and facile approach with a broad substrate scope, good yields, catalyst-free

  开发了一种用于制备具有生物学意义的吡啶并稠合喹唑啉酮和吡啶并[1,2- a ]苯并咪唑的无催化剂微波辅助环化方案。该反应涉及各种喹唑啉酮或苯并咪唑与 3-甲酰基色酮的 [3 + 3] 环化，生成官能化的 11 H-吡啶并[ 2,1- b ]喹唑啉-11-酮和吡啶并[1,2- a ]苯并咪唑衍生物。该方法成功地扩展到构建各种吡唑并[4,3 - d ]pyrido[1,2 - a ]pyrimidin-10(1 H）-那些。本方法是对现有合成方法的补充，并提供了一种快速简便的方法，具有广泛的底物范围、良好的收率、无催化剂条件和高官能团耐受性。最佳合成化合物也可用作“开关”光致发光探针，用于选择性检测 Fe 3+和 Ag +金属离子。
• SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1
  申请人：SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE

  公开号：US20150329497A1

  公开（公告）日：2015-11-19

  Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

  本文提供了小分子神经肽T受体激动剂，包括这些化合物的组合物和使用这些化合物和组合物的方法。
• Discovery of ML314, a Brain Penetrant Nonpeptidic β-Arrestin Biased Agonist of the Neurotensin NTR1 Receptor
  作者：Satyamaheshwar Peddibhotla、Michael P. Hedrick、Paul Hershberger、Patrick R. Maloney、Yujie Li、Monika Milewski、Palak Gosalia、Wilson Gray、Alka Mehta、Eliot Sugarman、Becky Hood、Eigo Suyama、Kevin Nguyen、Susanne Heynen-Genel、Stefan Vasile、Sumeet Salaniwal、Derek Stonich、Ying Su、Arianna Mangravita-Novo、Michael Vicchiarelli、Gregory P. Roth、Layton H. Smith、Thomas D. Y. Chung、Glen R. Hanson、James B. Thomas、Marc G. Caron、Lawrence S. Barak、Anthony B. Pinkerton

  DOI：10.1021/ml400176n

  日期：2013.9.12

  The neurotensin 1 receptor (NTR1) is an important therapeutic target for a range of disease states including addiction. A high-throughput screening campaign, followed by medicinal chemistry optimization, led to the discovery of a nonpeptidic beta-arrestin biased agonist for NTR1. The lead compound, 2-cyclopropyl-6,7-dimethoxy-4-(4-(2-methoxyphenyl)-piperazin-1-yl)quinazoline, 32 (ML314), exhibits full agonist behavior against NTR1 (EC50 = 2.0 mu M) in the primary assay and selectivity against NTR2. The effect of 32 is blocked by the NTR1 antagonist SR142948A in a dose-dependent manner. Unlike peptide-based NTR1 agonists, compound 32 has no significant response in a Ca2+ mobilization assay and is thus a biased agonist that activates the beta-arrestin pathway rather than the traditional G(q) coupled pathway. This bias has distinct biochemical and functional consequences that may lead to physiological advantages. Compound 32 displays good brain penetration in rodents, and studies examining its in vivo properties are underway.